Synthetic and natural monoamine oxidase inhibitors as potential lead compounds for effective therapeutics

Central Nervous System Agents in Medicinal Chemistry

Volumn 16, Issue 2, 2016, Pages 81-97

  Pathak, Ashish ^a   Srivastava, Amit K ^b   Singour, Pradeep K ^c   Gouda, Panchanan ^d  

^a Ravishankar College of Pharmacy   (India)

^b Sapience Bio Analytical Research Laboratory   (India)

^c VNS Group of Institutions   (India)

^d Khallikote College   (India)

Author keywords

Coumarins; Depression; Flavonoids; Monoamine oxidase inhibitors; Neurotransmitters; Parkinson s; Therapeutics; Xanthones

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; APIGENIN; BERGAPTEN; DOPAMINE RECEPTOR STIMULATING AGENT; EMODIN; ESCULETIN; EUPAFOLIN; IPROCLOZIDE; IPRONIAZID; ISOCARBOXAZID; LAZABEMIDE; LEUTEOLIN; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NATURAL PRODUCT; NEUROTRANSMITTER; PHENELZINE; PHENOXYPROPAZINE; PLANT EXTRACT; PSORALEN; QUERCETIN; RASAGILINE; SANGUINARINE; SCOPOLETIN; SELEGILINE; TAXIFOLIN; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIDEPRESSANT ACTIVITY; ARTEMISIA VULGARIS; ARTICLE; BIPOLAR DEPRESSION; COMPUTER AIDED DESIGN; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME STRUCTURE; MEDICINAL PLANT; MOLECULAR MODEL; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTRANSMISSION; PARKINSON DISEASE; PHYTOCHEMISTRY; STRUCTURE ACTIVITY RELATION; ANIMAL; DEPRESSION; ENZYMOLOGY; HUMAN; ISOLATION AND PURIFICATION; SYNTHESIS; TREATMENT OUTCOME;

ALZHEIMER DISEASE; ANIMALS; DEPRESSION; HUMANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PLANT EXTRACTS; PLANTS, MEDICINAL; TREATMENT OUTCOME;

EID: 84973598774     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/1871524915666150624120516     Document Type: Article

References (256)

1. Tipton, K.F. Enzymology of monoamine oxidase. Cell. Biochem.Funct., 1986, 4, 79-87.
2. Nagatsu, T.; Sawada, M. Molecular mechanism of the relation ofmonoamine oxidase B and its inhibitors to Parkinson’s disease:possible implications of glial cells. J. Neural. Transm., 2006, 71,53-65.
3. Gomes, B.; Naguwa, G.; Kloepfer, H.G.; Yasunobu, K.T; Amineoxidase, X V. The sulfhydryl groups of beef liver mitochondrialamine oxidase. Arch. Biochem. Biophys., 1969, 132, 28-33.
4. Minamiura, N.; Yasunobu, K.T. Bovine liver monoamine oxidase.A modified purification procedure and preliminary evidence fortwo subunits and one FAD. Arch. Biochem. Biophys., 1978, 189,481-489.
5. Harada, M.; Nagatsu, T. Identification of flavin in the purified beefliver mitochondrial monoamine oxidase. Experientia., 1969, 25,538-534.
6. Walker, W.H.; Kearney, E.B.; Seng, R.L.; Singer, T.P. Sequenceand structure of a cysteinyl flavin peptide from monoamine oxidase. Biochem. Biophys. Res. Commun., 1971, 44, 287-292.
7. Johnston, J.P. Some observations upon a new inhibitor of monoamineoxidase in brain tissue. Biochem. Pharmacol., 1968, 17,1285-1297.
8. Collins, G.G.S.; Sandler, M.; Williams, E.D.; Youdim, M.B.H. Multiple forms of human brain mitochondrial monoamine oxidase. Nature, 1970, 225, 817-820.
9. Shih, J.C. Cloning, after cloning, knock-out mice, and physiologicalfunctions of MAO A and B. Neurotoxicology, 2004, 25, 21-30.
10. Shih, J.C.; Chen, J.C.; Ridd, M.J. Monoamine oxidase: from geneto behavior. Ann. Rev. Neurosci., 1999, 22, 197-217.
11. Powell, J.F.; Huang, R.H.; Breakefield, X.O.; Craig, I.; Hsu, Y.P.P. Structure of the human gene for monoamine oxidase type A. Nucleic.Acids. Res., 1991, 19, 4537-4541.
12. Weyler, W.; Hsu, Y.P.P.; Breakefield, X.O. Biochemistry andgenetics of monoamine oxidase. Pharmac. Ther., 1990, 47, 391-417.
13. Ito, A.; Kuwahara, T.; Inadome, S.; Sagara, Y. Molecular cloningof a cDNA for rat liver monoamine oxidase B. Biochem. Biophys.Res. Commun., 1988, 157, 970-976.
14. Kwan, S.W.; Abell, C.W. cDNA cloning and sequencing of ratmonoamine oxidase A: comparison with the human and bovine enzymes. Comp. Biochem. Physiol., 1992, 102, 143-147.
15. Hsu, Y.P.; Weyler, W.; Chen, S.; Sims, K.B.; Rinehart, W.B.; Utterback, M.C.; Powell, J.F. Structural features of human monoamineoxidase A elucidated from cDNA and peptide sequences. J.Neurochem., 1988, 51, 1321-1324.
16. Chen, K.; Wu, H.F.; Shih, J.C. The deduced amino acid sequencesof human platelet and frontal cortex monoamine oxidase B areidentical. J. Neurochem., 1993, 61, 187-190.
17. Minamiura, N.; Yasunobu, K.T. Bovine liver monoamine oxidase.A modified purification procedure and preliminary evidence fortwo subunits and one FAD. Arch. Biochem. Biophys., 1978, 189,481-489.
18. Weyler, W. Monoamine oxidase A from human placenta andmonoamine oxidase from bovine liver both have one FAD persubunit. An important revision. Biochem. J., 1989, 260, 726-729.
19. Bach, A.W.J.; Lan, N.C.; Johnson, D.L.; Abell, C.W.; Bembenek, M.E.; Kwan, S.W.; Seeburg, P.H.; Shih, J.C. cDNA cloning of humanliver monoamine oxidase A and B: Molecular basis of differencesin enzymatic properties. Proc. Nat. Acad. Sci. U.S.A., 1989,85, 4934-4938.
20. Chen, Z.Y.; Hotamisligil, G.S.; Huang, J.K.; Wen, L.; Ezzeddine, D.; Aydin- Muderrisoglu, N.; Powell, J.F.; Huang, H.; Brealfield, X.O.; Craig, I.; Hsu, Y.P.P. Structure of the human gene for monoamineoxidase type A. Nucleic. Acids. Res., 1991, 19, 4537-4541.
21. Abell, C.W.; Kwan, S.W. Molecular characterization of monoamineoxidase A and B. Prog. Nucleic. Acid. Mol. Biol., 2001, 65,129-156.
22. Edmondson, D.E.; Binda, C.; Mattevi, A. The FAD binding sites ofhuman monoamine oxidases A and B. Neurotoxicology, 2004, 25,63-72.
23. Tsugeno, Y.; Hirashiki, I.; Ogata, F.; Ito, A. Regions of the moleculeresponsible for substrate specificity of monoamine oxidase Aand B: a chimeric enzyme analysis. J. Biochem., 1995, 118, 974-980.
24. Cesura, A.M.; Gottowik, J.; Lang, G.; Malherbe, P.; Da Prada, M.J. Structure-function relationships of mitochondrial monoamine oxidaseA and B: chimaeric enzymes and site-directed mutagenesisstudies. J. Neural. Transm., 1998, 52, 189-200.
25. Johnston, J.P. Some observations upon a new inhibitor of monoamineoxidase in brain tissue. Biochem. Pharmacol., 1968, 17,1285-1287.
26. Colibus L; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three-dimensional structure of human monoamineoxidase A (MAO A): relation to the structures of rat MAO A andhuman MAO B. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 12684-12689.
27. Nagatsu, T. Progress in monoamine oxidase (MAO) research inrelation to genetic engineering. Neurotoxicology, 2004, 25, 11-20.
28. Son, S.Y.; Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukihara, T. Structure of human monoamine oxidase A at 2.2-A°resolution: the control of opening the entry for substrates/inhibitors.Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 5739-5744.
29. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.E.; Mattevi, A. Structures of human monoamineoxidase B complexes with selective noncovalent inhibitors: safinamideand coumarin analogs. J. Med. Chem., 2007, 50, 5848-5852.
30. Youdim, M.B.; Bakhle, Y.S. Monoamine oxidase: isoforms andinhibitors in Parkinson´s disease and depressive illness. Br. J.Pharm., 2006, 147, S287-S296.
31. Edmondson, D.E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F. Structure and mechanism of monoamine oxidase. Curr. Med.Chem., 2004, 11, 1983-1993.
32. Saura, J.; Luque, J.M.; Cesura, A.M.; Da Prada, M.; Chan-Palay, V.; Huber, G.; Loffler, J.; Richards, J.G. Increased monoamineoxidase B activity in plaque-associated astrocytes of Alzheimerbrains revealed by quantitative enzyme radioautography. Neuroscience,1994, 62, 15-30.
33. Rang, H. P.; Dale, M. M.; Ritter, J. M.; Flower, R. J. Pharmacology,6th ed.; Churchill Vingstone, Elsevier: London, 2008.
34. Kitahama, K.; Maeda, T.; Denney, R.M.; Jouvet, M. Monoamineoxidase: distribution in the cat brain studied by enzyme- and immunohistochemistry:recent progress. Progr. Neurobiol., 1994, 42,53-78.
35. Luque, J.M.; Biou, V.; Nicholls, J.G. Three-dimensional visualizationof the distribution, growth, and regeneration of monoaminergicneurons in whole mounts of immature mammalian CNS. J. Compar.Neurol., 1998, 390, 427-438.
36. Konradi, C.; Kornhuber, J.; Froelich, L.; Fritze, J.; Heisen, H.; Beckmann, H.; Schultz, E.; Riederer, P. Demonstration of monoamineoxidase-A and -B in the human brainstem by a histochemicaltechnique. Neuroscience, 1989, 33, 383-400.
37. Westlund, K.N.; Denney, R.M.; Rose, R.M.; Abell, C.W. Localizationof distinct monoamine oxidase A and monoamine oxidase Bcell populations in human brainstem. Neuroscience, 1988, 25, 439-456.
38. Youdim, M.B.H.; Finberg, J.P.M.; Tipton, K.F. In: CatecholamineII; Trendelenburg, U.; Weiner, N. Ed.; Springer: Berlin, 1988; 127-199.
39. Nicotra, A.; Pierucci, F.; Parvez, H.; Senatori, O. Monoamineoxidase expression during development and aging. Neurotoxicology,2004, 25, 155-165.
40. Tsang, D.; Ho, K.P.; Wen, H.L. Ontogenesis of multiple forms ofmonoamine oxidase in rat brain regions and liver. Dev. Neurosci.,1986, 8, 243-250.
41. Strolin B.M.; Dostert, P.; Tipton, K.F. Developmental aspects ofthe monoamine-degrading enzyme monoamine oxidase. Dev.Pharmacol. Ther., 1992, 18, 191-200.
42. O’Carroll A.M.; Fowler C.J.; Phillips J.P.; Tobbia I.; Tipton K.F.The deamination of dopamine by human brain monoamine oxidase.Specificity for the two enzyme forms in seven brain regions.Naunyn. Schmiedeberg’s. Arch. Pharmacol., 1983, 322, 198-202.
43. Westlund, K.N.; Denney, R.M.; Kochersperger, L.M.; Rose, R.M.; Abell, C.W. Distinct monoamine oxidase A and B populations inprimate brain. Science, 1985, 230, 181-183.
44. Westlund, K.N.; Denney, R.M.; Rose, R.M.; Abell, C.W. Localizationof distinct monoamine oxidase A and monoamine oxidase Bcell populations in human brain-stem. Neuroscience, 1988, 25, 439-456.
45. Willoughby, J.; Glover, V.; Sandler, M. Histochemical localisationof monoamine oxidase A and B in rat brain. J. Neural. Transm.,1988,74, 29-42.
46. Saura, J.; Kettler, R.; Da Prada, M.; Richards, J.G. Quantitativeenzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327in vitro: localiza-tion and abundance of MAO-A and MAO-B in ratCNS, peripheral organs, and human brain. J. Neurosci., 1992, 12,1977-1999.
47. Saura, J.; Bleuel, Z.; Ulrich, J.; Mendelowitsch, A.; Chen, K.; Shih, J.C.; Malherbe, P.; Da Prada, M.; Richards, J.G. Molecular neuroanatomyof human monoamine oxidases A and B revealed by quantitativeenzyme radioautography and in situ hybridization histochemistry. Neuroscience, 1996, 70, 755-774.
48. Richards, J.G.; Saura, J.; Ulrich, J.; Da Prada, M. Molecular neuroanatomyof monoamine oxidases in human brainstem. Psychopharmacology.(Berl)., 1992, 106, S21-S23.
49. Arai, R.; Kimura, H.; Nagatsu, I.; Maeda, T. Preferential localizationof monoamine oxidase type A in neurons of the locus coeruleusand type B activity in neurons of the dorsal raphe nucleus ofthe rat: a detailed enzyme histochemical study. Brain. Res., 1997,745, 352-356.
50. Jahung, J.W.; Houpt, T.A.; Wessel, T.C.; Chen, K.; Shih, J.C. Localization of monoamine oxidase A and B mRNA in the ratbrain by in situ hybridization. Synapse., 1997, 25, 30-36.
51. Luque, J.M.; Kwan, S.W.; Abell, C.W.; Da Prada, M.; Richards, G.J. Cellular expression of mRNAs encoding monoamine oxidaseA and B in the rat central nervous system. J. Comp. Neurol., 1995,363, 665–680.
52. Saura, J.; Richards, J.G.; Mahy, N.; Age-related changes in MAOin Bl/C57 mouse tissues: a quantitative radioautography study. J.Neural. Transm., 1994, 41, 89-94.
53. Westlund, K.N.; Denney, R.M.; Rose, R.M.; Abell, C.W. Localizationof distinct monoamine oxidase A and monoamine oxidase B inrat brain. J. Neural. Transm., 1988, 7, 29-42.
54. Egashira, T.; Yamanaka, Y. Further studies on the synthesis of Aformof MAO. Jap. J. Pharmacol., 1981, 31, 763-770.
55. Bond, P.A.; Cundall, R.L. Properties of monoamine oxidase(MAO) in human blood platelets, plasma, lymphocytes and granulocytes. Clin. Chim. Acta., 1977, 80, 317-326.
56. Donnelly, C.H.; Murphy, D.L. Substrate and inhibitor-related characteristicsof human platelet monoamine oxidase. Biochem. Pharmacol.,1977, 26, 853-858.
57. Nagatsu, T. Progress in monoamine oxidase (MAO) research inrelation to genetic engineering. Neurotoxicology, 2004, 25, 11-20.
58. Nicotra, A.; Parvez, S.H.; Glover, V.; Sandler, M.; Parvez, S.; Minami, M. Monoamine oxidases: molecular, pharmacologicaland neurotoxicological aspects, Elsevier: Amsterdam, 2004.
59. Riederer, P.; Youdim, M.B.H. In: Amine Oxidases and Their Impacton Neurobiology, Proceedings of the 4th International AmineOxidases Workshop, Wurzburg, Federal Republic of Germany,July 7-10, 1990; J. Neural. Transm., 1990, 32, 1-491.
60. Youdim, M.B.; Riederer, P. Understanding Parkinson’s disease. Sci. Am., 1997, 276, 52-59.
61. Youdim, M.B.H.; Edmondson, D.; Tipton, K.F. The therapeuticpotential of monoamine oxidase inhibitors. Nat. Rev. Neurosci.,2006, 7, 295-309.
62. Shih, J.C.; Chen, K.; Ridd, M.J. Monoamine oxidase: From genesto behavior. Annu. Rev. Neurosci., 1999, 22, 197-217.
63. Bach, A.W.; Lan, N.C.; Johnson, D.L.; Abell, C.W.; Bembenek, M.E.; Kwan, S.W.; Seeburg, P.H.; Shih, J.C. cDNA cloning of humanliver monoamine oxidase A and B: molecular basis of differencesin enzymatic properties. Proc. Nat. Acad. Sci., 1988, 85,4934-4938.
64. Youdim, M.B.; Edmondson, D.; Tipton, K.F. The therapeutic potentialof monoamine oxidase inhibitors. Nat. Rev. Neurosci., 2006,7, 295-309.
65. Liccione, J.; Azzaro, A.J.; Different roles for type A and type Bmonoamine oxidase in regulating synaptic dopamine at D-1 and D-2 receptors associated with adenosine-3’,5’-cyclic monophosphate(cyclic AMP) formation. Naunyn. Schmiedeberg’s. Arch. Pharmacol.,1988, 337, 151-158.
66. Halliwell, B. Reactive oxygen species and the central nervoussystem. J. Neurochem., 1992, 59, 1609-1623.
67. Yang, L.; Omori, K.; Suzukawa, J.; Inagaki, C. CalcineurinmediatedBAD Ser155 dephosphorylation in ammonia-inducedapoptosis of cultured rat hippocampal neurons. Neurosci. Lett.,2004, 357, 73-75.
68. Klann, E.; Thiels, E. Modulation of protein kinases and proteinphosphatases by reactive oxygen species: implications for hippocampalsynaptic plasticity. Prog. Neuropsychopharmacol. Biol.Psychiatry., 1999, 23, 359-376.
69. Nistico, R.; Piccirilli, S.; Cucchiaroni, M.L.; Armogida, M.; Guatteo, E.; Giampo, C.; Fusco, F.R.; Bernardi, G.; Nistico, G.; Mercuri, N.B. Neuroprotective effect of hydrogen peroxide on an in vitromodel of brain ischaemia. Br. J. Pharmacol., 2008, 153, 1022-1029.
70. Armogida, M.; Nistico, R.; Mercuri, N.B. Therapeutic potential oftargeting hydrogen peroxide metabolism in the treatment of brainischaemia. Br. J. Pharmacol., 2012, 166, 1211-1224.
71. Bortolato, M.; Chen, K.; Shih, J.C. Monoamine oxidase inactivation:from pathophysiology to therapeutics. Adv. Drug. Deliv. Rev.,2008, 60, 1527-1533.
72. Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO inhibitors:safety and future. Neurotoxicology, 2004, 25, 215-221.
73. Pessayre, D.; de Saint-Louvent, P.; Degott, C.; Bernuau, J.; Rueff, B.; Benhamou, J.P. Iproclozide fulminant hepatitis. Possible role ofenzyme induction. Gastroenterology, 1978, 75, 492-496.
74. Fentem, P.H.; Howitt, G. Fatal Jaundice after Administration ofPheniprazine. Br. Med. J., 1961, 2, 1616-1617.
75. Imlah, N.W.; Preliminary report on phenoxypropazine. Am. J.Psychiatry, 1963, 119, 1091-1092.
76. Yanez, M.; Padin, J.F.; Arranz-Tagarro, J.A.; Camina, M.; Laguna, R. History and therapeutic use of MAO-A inhibitors: a historicalperspective of mao-a inhibitors as antidepressant drug. Curr. Top.Med. Chem., 2012, 12, 2275-2282.
77. Da Prada, M.; Zurcher, G.; Wurthrich, I.; Haefely, W.E. Ontyramine, food beverages and the reversible MAO inhibitor moclobemide. J. Neural. Transm., 1988, 26, 33-56.
78. Bonnet, U. Moclobemide: therapeutic use and clinical studies.CNS. Drug. Rev., 2003, 9, 97-140.
79. Palhagen, S.; Heinonen, E.; Hagglund, J.; Kaugesaar, T.; Maki-Ikola, O.; Palm, R. Selegiline slows the progression of the symptomsof Parkinson disease. Neurology, 2006, 66, 1200-1206.
80. Pacher, P.; Kecscekmeti, V. Trends in the development of newantidepressants. Is there a light at the end of the tunnel?. Curr.Med. Chem., 2004, 11, 925-943.
81. Provost, J.C.; Funck-Brentano, C.; Rovei, V.; D’Estanque, J.; Ego, D.; Jaillon, P. Pharmacokinetic and pharmacodynamic interactionbetween toloxatone, a new reversible monoamine oxidase-A inhibitor,and oral tyramine in healthy subjects. Clin. Pharmacol. Ther.,1992, 52, 384-393.
82. Da Prada, M.; Kettler, R.; Keller, H.H.; Cesura, A.M.; Richards, J.G.; Saura M.J.; Muggli-Maniglio, D.; Wyss, P.C.; Kyburz, E.; Imhof, R. From moclobemide to Ro 19-6327 and Ro 41-1049: thedevelopment of a new class of reversible, selective MAO-A andMAO-B inhibitors. J. Neural. Transm., 1990, 29, 279-292.
83. Anderson, M.C.; Hasan, F.; McCrodden, J.M.; Tipton, K.F. Monoamineoxidase inhibitors and the cheese effect. Neurochem. Res.,1993, 18, 1145-1149.
84. Di Monte D.A.; DeLanney, L.E.; Irwin, I.; Royland, J.E.; Chan, P.; Jacowec, M.W.; Langston, J.W. Monoamine oxidase-dependentmetabolism of dopamine in the striatum and substantia nigra of LDOPA-treated monkeys. Brain Res., 1996, 738, 53-59.
85. Finberg, J.P.; Takeshima, T.; Johnston, J.M.; Commissiong, J.W.; Increased survival of dopaminergic neurons by rasagiline, a monoamineoxidase B inhibitor. Neuroreport., 1998, 9, 703-707.
86. Tabakman, R.; Lecht, S.; Lazarovici, P.; Neuroprotection by monoamineoxidase B inhibitors: A therapeutic strategy for Parkinson'sdisease?. Bioessays., 2004, 26, 80-90.
87. Jenner, P. Preclinical evidence for neuroprotection with monoamineoxidase-B inhibitors in Parkinson's disease. Neurology,2004, 63, S13-S22.
88. deMarcaida, J.A.; Schwid, S.R.; White, W.B.; Blindauer, K.; Fahn, S.; Kieburtz, K.; Stern, M.; Shoulson, I.; Parkinson Study GroupTEMPO; PRESTO Tyramine Substudy Investigators and Coordinators.Effects of tyramine administration in Parkinson's disease patientstreated with selective MAO-B inhibitor rasagiline. Mov. Disord.,2006, 21, 1716-1721.
89. Goren, T.; Adar, L.; Sasson, N.; Weiss, Y.M. Clinical pharmacologytyramine challenge study to determine the selectivity of themonoamine oxidase type B (MAO-B) inhibitor rasagiline. J. Clin.Pharmacol., 2010, 50, 1420-1428.
90. Finberg, J.P.; Gillman, K. Selective inhibitors of monoamine oxidasetype B and the "cheese effect". Int. Rev. Neurobiol., 2011,100, 169-90.
91. Chen, J.J.; Wilkinson, J.R. The monoamine oxidase type B inhibitorrasagiline in the treatment of Parkinson disease: is tyramine achallenge?. J. Clin. Pharmacol., 2012, 52, 620-628.
92. Hoy, S.M.; Keating, G.M. Rasagiline: a review of its use in thetreatment of idiopathic Parkinson's disease. Drugs, 2012, 72, 643-669.
93. Geha, R.M.; Chen, K.; Wouters, J.; Ooms, F.; Shih, J.C. Analysisof conserved active site residues in monoamine oxidase A and Band their three-dimensional molecular modeling. J. Biol. Chem.,2002, 277, 17209-17216.
94. Guay, D.R. Rasagiline (TVP-1012): a new selective monoamineoxidase inhibitor for Parkinson's disease. Am. J. Geriatr. Pharmacother.,2006, 4, 330-346.
95. Riederer, P.; Danielczyk, W.; Grunblatt, E. Monoamine oxidase-binhibition in Alzheimer’s disease. Neurotoxicology, 2004, 25, 271-277.
96. Fernandez, H.H.; Chen, J.J. Monamine oxidase inhibitors: currentand emerging agents for Parkinson disease. Clin. Neuropharmacol.,2007, 30, 150-168.
97. Fiedorowicz, J.G.; Swartz, K.L. The Role of Monoamine OxidaseInhibitors in Current Psychiatric Practice. J. Psychiatr. Pract.,2004, 10, 239-248.
98. Gillman, P.K. Monoamine oxidase inhibitors, opioid analgesics andserotonin toxicity. Br. J. Anaesth., 2005, 95, 434-441.
99. Otte, W.; Birkenhager, T.K.; Van den Broek, W.W. Fatal interactionbetween tranylcypromine and imipramine. Eur. Psychiatry,2003, 18, 264-265.
100. Cassens, S.; Nickel, E.A.; Quintel, M.; Neumann, P. The serotoninsyndrome. Fatal course of intoxication with citalopram and moclobemide. Anaesthesist., 2006, 55, 1189-1196.
101. Zonneveld, A.M.; Hagenaars, M.; Voermans, N.C.; Gelissen, H.P.; Claassen, J.A. Life-threatening serotonin syndrome following asingle dose of a serotonin reuptake inhibitor during maintenancetherapy with a monoamine oxidase inhibitor. Ned. Tijdschr.Geneeskd., 2006, 150, 1081-1084.
102. Gillman, P.K. Serotonin syndrome: history and risk. Fund. Clin.Pharmacol., 1998, 12, 482-491.
103. Gillman, P.K. A review of serotonin toxicity data: implications forthe mechanisms of antidepressant drug action. Biol. Psychiatry.,2006, 59, 1046-1051.
104. Gillman, P.K.; Whyte, I.M. Serotonin Syndrome. Oxford UniversityPress: Oxford, 2004.
105. Gillman, P.K. Tricyclic antidepressant pharmacology and therapeuticdrug interactions updated. Br. J. Pharmacol., 2007, 151, 737-748.
106. Ramsay, R.R.; Dunford, C.; Gillman, P.K. Methylene blue andserotonin toxicity: inhibition of monoamine oxidase A (MAO A)confirms a theoretical prediction. Br. J. Pharmacol., 2007, 152,946-951.
107. Pare, C.M.; Kline, N.; Hallstrom, C.; Cooper, T.B. Will amitriptylineprevent the ‘cheese’ reaction of monoamine-oxidase inhibitors?.Lancet., 1982, 2, 183-186.
108. Dostert, P.; Castelli, M.G.; Cicioni, P.; Strolin Benedetti, M. Reboxetineprevents the tranylcypromine-induced increase intyramine levels in rat heart. J. Neural. Transm., 1994, 41, 149-153.
109. Gillman, P.K. Linezolid and serotonin toxicity. Clin. Infect. Dis.,2003, 37, 1274-1275.
110. Gillman, P.K. Comment on: serotonin syndrome due to coadministrationof linezolid and venlafaxine. J. Antimicrob. Chemother.,2004, 54, 844-845.
111. Lawrence, K.R.; Adra, M.; Gillman, P.K. Serotonin toxicity associatedwith the use of linezolid: a review of postmarketing data. Clin.Infect. Dis., 2006, 42, 1578-1583.
112. Sola, C.L.; Bostwick, J.M.; Hart, D.A.; Lineberry, T.W. Anticipatingpotential linezolid-SSRI interactions in the general hospital setting:an MAOI in disguise. Mayo. Clin. Proc., 2006, 81, 330-334.
113. Taylor, J.J.; Wilson, J.W.; Estes, L.L. Linezolid and serotonergicdrug interactions: a retrospective survey. Clin. Infect. Dis., 2006,43, 180-187.
114. Lane, R.; Baldwin, D. Selective serotonin reuptake inhibitor–induced serotonin syndrome: review. J. Clin. Psychopharmacol.,1997, 17, 208-221.
115. Cooper, B.E.; Sejnowski, C.A. Serotonin syndrome: recognitionand treatment. AACN. Adv. Crit. Care, 2013, 24, 15-20.
116. Shakoor, M.; Ayub, S.; Ahad, A.; Ayub, Z. Transient serotoninsyndrome caused by concurrent use of tramadol and selective serotoninreuptake inhibitor. Am. J. Case. Rep., 2014, 15, 562-564.
117. Tao, R.; Rudacille, M.; Zhang, G.; Ma, Z. Changes in intensity ofserotonin syndrome caused by adverse interaction between monoamineoxidase inhibitors and serotonin reuptake blockers. Neuropsychopharmacology,2014, 39, 1996-2007.
118. Pletscher, A. The discovery of antidepressants: a winding path. Experientia., 1991, 47, 4-8.
119. Zisook, S.E. Clinical overview of monoamine oxidase inhibitors. Psychosomatics., 1985, 26, 240-251.
120. Thase, M.E. MAOIs and depression treatment guidelines. J. Clin.Psychiatry, 2012, 73, e24.
121. VanDenBerg, C.M. The transdermal delivery system of monoamineoxidase inhibitors. J. Clin. Psychiatry, 2012, 73, 25-30.
122. Gareri, P.; Falconi, U.; De Fazio, P.; De Sarro, G. Conventionaland new antidepressant drugs in the elderly. Progr. Neurobiol.,2000, 61, 353-396.
123. Kier, A.; Han, J.; Jacobson, L. Chronic treatment with the monoamineoxidase inhibitor phenelzine increases hypothalamicpituitary-adrenocortical activity in male C57BL/6 mice: relevanceto atypical depression. Endocrinology, 2005, 146, 1338-1347.
124. Kasckow, J.W.; Baker, D.; Geracioti, T.D. Corticotropin-releasinghormone in depression and post-traumatic stress. Peptides, 2001,22, 845-851.
125. Jankovic, J. Parkinson's disease: clinical features and diagnosis. J.Neurol. Neurosurg. Psychiatry, 2008, 79, 368-376.
126. Yasar, S.; Goldberg, J.P.; Goldberg, S.R. Are metabolites of ldeprenyl(selegiline) useful or harmful? Indications from preclinicalresearch. J. Neural. Transm. Suppl., 1996, 48, 61-73.
127. Ondo, W.G.; Sethi, K.D.; Kricorian, G. Selegiline orally disintegratingtablets in patients with Parkinson disease and "wearing off"symptoms. Clin. Neuropharmacol., 2007, 30, 295-300.
128. Mawhinney, M.; Cole, D.; Azzaro, A.J. Daily transdermal administrationof selegiline to guinea-pigs preferentially inhibits monoamineoxidase activity in brain when compared with intestinal andhepatic tissues. J. Pharm. Pharmacol., 2003, 55, 27-34.
129. Fowler, J.S.; Logan, J.; Volkow, N.D.; Shumay, E.; McCall-Perez, F.; Jayne, M.; Wang, G.J.; Alexoff, D.L.; Apelskog-Torres, K.; Hubbard, B.; Carter, P.; King, P.; Fahn, S.; Gilmor, M.; Telang, F.; Shea, C.; Xu, Y.; Muench, L. Evidence that formulations of the selectiveMAO-B inhibitor, selegiline, which bypass first-pass metabolism,also inhibit MAO-A in the human brain. Neuropsychopharmacology,2015, 40, 650-657.
130. Azzaro, A.J.; Vandenberg, C.M.; Blob, L.F.; Kemper, E.M.; Sharoky, M.; Oren, D.A.; Campbell, B.J. Tyramine pressor sensitivityduring treatment with the selegiline transdermal system 6mg/24 h in healthy subjects. J. Clin. Pharmacol., 2006, 46, 933-944.
131. Bodkin, J.A.; Amsterdam, J.D. Transdermal selegiline in majordepression: a double-blind, placebo-controlled, parallel-groupstudy in outpatients. Am. J. Psychiatry, 2002, 159, 1869-1875.
132. Amsterdam, J.D. A double-blind, placebo-controlled trial of thesafety and efficacy of selegiline transdermal system without dietaryrestrictions in patients with major depressive disorder. J. Clin. Psychiatry,2003, 64, 208-214.
133. Feiger, A.D.; Rickels, K.; Rynn, M.A.; Zimbroff, D.L.; Robinson,D.S. Selegiline transdermal system for the treatment of major depressivedisorder: an 8-week, double-blind, placebo-controlled,flexible-dose titration trial. J. Clin. Psychiatry, 2006, 67, 1354-1361.
134. Clarke, A.; Brewer, F.; Johnson, E.S.; Mallard, N.; Hartig, F.; Taylor, S.; Corn, T.H. A new formulation of selegiline: improvedbioavailability and selectivity for MAO-B inhibition. J. Neural.Transm., 2003, 110, 1241-1255.
135. Lohle, M.; Storch, A. Orally disintegrating selegiline for the treatmentof Parkinson’s disease. Expert. Opin. Pharmacother., 2008, 9,2881-2891.
136. Marconi, S.; Zwingers, T. Comparative efficacy of selegiline versusrasagiline in the treatment of early Parkinson's disease. Eur.Rev. Med. Pharmacol. Sci., 2014, 18, 1879-1882.
137. Jankovic, J.; Berkovich, E.; Eyal, E.; Tolosa, E. Symptomatic efficacyof rasagiline monotherapy in early Parkinson's disease: posthocanalyses from the ADAGIO trial. Parkinsonism. Relat. Disord.,2014, 20, 640-643.
138. Muller, T. Current status of safinamide for the drug portfolio ofParkinson's disease therapy. Expert. Rev. Neurother., 2013, 13,969-977.
139. Dezsi, L.; Vecsei, L. Safinamide for the treatment of Parkinson'sdisease. Expert. Opin. Investig. Drugs, 2014, 23, 729-742.
140. Swerdlow, R.H. Pathogenesis of Alzheimer’s disease. Clin. Interv.Aging., 2007, 2, 347-359.
141. Thomas, T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol. Aging., 2000, 21, 343-348.
142. Riederer, P.; Danielczyk, W.; Grunblatt, E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology, 2004, 25, 271-277.
143. Samadi, A.; de los Rios, C.; Bolea, I.; Chioua, M.; Iriepa, I.; Moraleda, I.; Bartolini, M.; Andrisano, V.; Galvez, E.; Valderas, C.; Unzeta, M.; Marco-Contelles, J.; Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine. Eur. J. Med. Chem., 2012, 52, 251-262.
144. Bautista-Aguilera, O.M.; Esteban, G.; Chioua, M.; Nikolic, K.; Agbaba, D.; Moraleda, I.; Iriepa, I.; Soriano, E.; Samadi, A.; Un zeta, M.; Marco-Contelles, J.; Multipotent cholinesterase/ monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids. Drug. Des. Devel. Ther., 2014, 13, 1893-1910.
145. Delumeau, J.C.; Bentue-Ferrer, D.; Gandon, J.M.; Amrein, R.; Belliard, S.; Allain, H. Monoamine oxidase inhibitors, cognitivefunctions and neurodegenerative diseases. J. Neural. Transm.Suppl., 1994, 41, 259-266.
146. Soto, J.; Ulibarri, I.; Jauregui, J.V.; Ballesteros, J.; Meana, J.J. Dissociation between I2-imidazoline receptors and MAO-B activityin platelets of patients with Alzheimer’s type dementia. J. Psychiatr.Res., 1999, 33, 251-257.
147. Cai, Z. Monoamine oxidase inhibitors: promising therapeuticagents for Alzheimer's disease (Review). Mol. Med. Rep., 2014, 9,1533-1541.
148. Weinreb, O.; Mandel, S.; Bar-Am, O.; Amit, T. Iron-chelatingbackbone coupled with monoamine oxidase inhibitory moiety asnovel pluripotential therapeutic agents for Alzheimer’s disease: atribute to Moussa Youdim. J. Neural. Transm., 2011, 118, 479-492.
149. Zheng, H.; Fridkin, M.; Youdim, M.B. Site-activated chelatorsderived from anti-Parkinson drug rasagiline as a potential safer andmore effective approach to the treatment of Alzheimer’s disease. Neurochem. Res., 2010, 35, 2117-2123.
150. Zheng, H.; Weiner, L.M.; Bar-Am, O.; Epsztejn, S.; Cabantchik, Z.I.; Warshawsky, A.; Youdim, M.B.; Fridkin, M. Design, synthesis,and evaluation of novel bifunctional iron-chelators as potentialagents for neuroprotection in Alzheimer’s, Parkinson’s, and otherneurodegenerative diseases. Bioorg. Med. Chem., 2005, 13, 773-783.
151. Yang, H.Q.; Ba, M.W.; Ren, R.J.; Zhang, Y.H.; Ma, J.F.; Pan, J.; Lu, G.Q.; Chen, S.D. Mitogen activated protein kinase and proteinkinase C mediated promotion of sAPPα by deprenyl. Neurochem.Int., 2007, 50, 74-82.
152. Hong-Qi, Y.; Zhi-Kun, S.; Sheng-Di, C. Current advances in thetreatment of Alzheimer's disease: focused on considerations targetingAβ and tau. Transl. Neurodegener., 2012, 1, 21.
153. Youdim, M.B.H.; Weinstock, M. Molecular basis of neuroprotectiveactivities of rasagiline and the anti-Alzheimer drug, TV3326, [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate]. Cell. Mol. Neurobiol., 2002, 21, 555-573.
154. Weinstock, M.; Gorodetsky, E.; Poltyrev, T.; Gross, A.; Sagi, Y.; Youdim, M. A novel cholinesterase and brain-selective monoamineoxidase inhibitor for the treatment of dementia comorbid with depressionand Parkinson’s disease. Prog. Neuropsychopharmacol.Biol. Psychiatry., 2003, 27, 555-561.
155. Yanez, M.; Vina, D. Dual inhibitors of monoamine oxidase andcholinesterase for the treatment of Alzheimer disease. Curr. Top.Med. Chem., 2013, 13, 1692-1706.
156. Fowler, J.S.; Logan, J.; Azzaro, A.J.; Fielding, R.M.; Zhu, W.; Poshusta, A.K.; Burch, D.; Brand, B.; Free, J.; Asgharnejad, M.; Wang, G.J.; Telang, F.; Hubbard, B.; Jayne, M.; King, P.; Carter, P.; Carter, S.; Xu, Y.; Shea, C.; Muench, L.; Alexoff, D.; Shumay, E.; Schueller, M.; Warner, D.; Apelskog-Torres, K. Reversible inhibitorsof monoamine oxidase-A (RIMAs): robust, reversible inhibitionof human brain MAO-A by CX157. Neuropsychopharmacology,2010, 35, 623-631.
157. Pisani, L.; Muncipinto, G.; Miscioscia, T.F.; Nicolotti, O.; Leonetti, F.; Catto, M.; Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarez, E.; Passeleu, C.; Carotti, A. Discovery of a novel class ofpotent coumarin monoamine oxidase B inhibitors: developmentand biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate(NW-1772) as a highly potent, selective, reversible, and orally activemonoamine oxidase B inhibitor. J. Med. Chem., 2009, 52,6685-6706.
158. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.E.; Mattevi, A. Structures of human monoamineoxidase B complexes with selective noncovalent inhibitors: safinamideand coumarin analogs. J. Med. Chem., 2007, 50, 5848-5852.
159. Vilar, S.; Ferino, G.; Quezada, E.; Santana, L.; Friedman, C. Predictingmonoamine oxidase inhibitory activity through ligandbasedmodels. Curr. Top. Med. Chem., 2012, 12, 2258-2274.
160. Reniers, J.; Robert, S.; Frederick, R.; Masereel, B.; Vincent, S.; Wouters, J. Synthesis and evaluation of β-carboline derivatives aspotential monoamine oxidase inhibitors. Bioorg. Med. Chem.,2011, 19, 134-144.
161. Strydom, B.; Malan, S.F.; Castagnoli N, Jr.; Bergh, J.J.; Petzer, J.P. Inhibition of monoamine oxidase by 8- benzyloxycaffeine analogues. Bioorg. Med. Chem., 2010, 18, 1018-1028.
162. Meiring, L.; Petzer, J.P.; Petzer, A. Inhibition of monoamine oxidaseby 3,4-dihydro-2(1H)-quinolinone derivatives. Bioorg. Med.Chem. Lett., 2013, 23, 5498-5502.
163. Prins, L.H.; Petzer, J.P.; Malan, S.F. Inhibition of monoamineoxidase by indole and benzofuran derivatives. Eur. J. Med. Chem.,2010, 45, 4458-4466.
164. Chapman, A.G.; Hart, G.P. Anticonvulsant drug action and regionalneurotransmitter amino acid changes. J. Neural. Transm.,1988, 72, 201-212.
165. Silverman, R.B.; Nishimura, K.; Lu, X. Mechanism of inactivationof monoamine oxidase-B by the anticonvulsant agent milacemide(2-(n-pentylamino)acetamide). J. Am. Chem. Soc., 1993, 115,4949-4954.
166. Shen, W.; Yu, S.; Zhang, J.; Jia, W.; Zhu, Q. Synthesis and BiologicalEvaluation of 2-Phenoxyacetamide Analogues, a NovelClass of Potent and Selective Monoamine Oxidase Inhibitors.Molecules, 2014, 19, 18620-18631.
167. Pan, Z.X.; He, X.; Chen, Y.Y.; Tang, W.J.; Shi, J.B.; Tang, Y.L.; Song, B.A.; Li, J.; Liu, X.H. New 2H-chromene-3-carboxamide derivatives:design, synthesis and use as inhibitors of hMAO. Eur. J.Med. Chem., 2014, 80, 278-284.
168. Mattsson, C.; Svensson, P.; Sonesson, C. A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selectivemonoamine oxidase (MAO) A inhibitors. Eur. J. Med. Chem.,2014, 73, 177-186.
169. Desideri, N.; Fioravanti, R.; Proietti Monaco, L.; Biava, M.; Yanez, M.; Ortuso, F.; Alcaro, S. 1,5-Diphenylpenta-2,4-dien-1-ones aspotent and selective monoamine oxidase-B inhibitors. Eur. J. Med.Chem., 2013, 59, 91-100.
170. Legoabe, L.J.; Petzer, A.; Petzer, J.P. α -Tetralone derivatives asinhibitors of monoamine oxidase. Bioorg. Med. Chem. Lett., 2014,24, 2758-2763.
171. Ven Murthy, M.R.; Ranjekar, P.K.; Ramassamy, C.; Deshpande, M. Scientific basis for the use of Indian ayurvedic medicinal plantsin the treatment of neurodegenerative disorders: ashwagandha. Cent. Nerv. Syst. Agents. Med. Chem., 2010, 10, 238-246.
172. Kumar, G.P.; Khanum, F. Neuroprotective potential of phytochemicals.Pharmacogn. Rev., 2012, 6, 81-90.
173. Vina, D.; Serra, S.; Lamela, M.; Delogu, G. Herbal natural productsas a source of monoamine oxidase inhibitors: a review. Curr. Top.Med. Chem., 2012, 12, 2131-2144.
174. Mazzio, E.; Deiab, S.; Park, K.; Soliman, K.F.A. High throughputScreening to Identify Natural Human Monoamine Oxidase B Inhibitors. Phytother. Res., 2013, 27, 818-828.
175. Stringer, T.P.; Guerrieri, D.; Vivar, C.; van Praag, H. Plant-derivedflavanol (−)epicatechin mitigates anxiety in association with elevatedhippocampal monoamine and BDNF levels, but does not influencepattern separation in mice. Transl. Psychiatry, 2015, 5,e493.
176. Mathew, B.; Suresh, J.; Mathew, G.E.; Parasuraman, R.; AbdullaN. Plant Secondary Metabolites- Potent Inhibitors of MonoamineOxidase Isoforms. Cent. Nerv. Syst. Agents. Med. Chem., 2014, 14,28-33.
177. Herraiz, T.; Chaparro, C. Human monoamine oxidase is inhibitedby tobacco smoke: beta-carboline alkaloids act as potent and reversibleinhibitors. Biochem. Biophys. Res. Commun., 2005, 326,378-386.
178. Cui, Y.X.; Xiao, Q.; Tu, P.F. A concise approach to the synthesisof carnosic acid type diterpenes. Chin. Chem. Lett., 2001, 12, 203-204.
179. Bembenek, M.E.; Abell, C.W.; Chrisey, L.A.; Rozwadowska, M.D.; Gessner, W.; Brossi, A. Inhibition of monoamine oxidases Aand B by simple isoquinoline alkaloids: racemic and optically active1,2,3,4tetrahydro-,3,4-dihydro- and fully aromatic isoquinolines.J. Med. Chem., 1990, 33, 147-152.
180. Rendenbach-Muller, B.; Schlecker, R.; Traut, M.; Weifenbach, H.Synthesis of coumarins as subtype-selective inhibitors of monoamineoxidase. Bioorg. Med. Chem. Lett., 1994, 4, 1195-1198.
181. Gnerre, C.; Catto, M.; Leonetti, F.; Weber, P.; Carrupt, P.A.; Altomare, C.; Carotti, A.; Testa, B. Inhibition of monoamine oxi dases by functionalized coumarin derivatives: biological activities,QSARs, and 3D-QSARs. J. Med. Chem., 2000, 43, 4747-4758.
182. Huong, D.T.; Choi, H.C.; Rho, T.C.; Lee, H.S.; Lee, M.K.; Kim, Y.H. Inhibitory activity of monoamine oxidase by coumarins fromPeucedanum japonicum. Arch. Pharm. Res., 1999, 22, 324-326.
183. Carotti, A.; Carrieri, A.; Chimichi, S.; Boccalini, M.; Cosimelli, B.; Gnerre, C.; Carotti, A.; Carrupt, P.A.; Testa, B. Natural and syntheticgeiparvarins are strong and selective MAO-B inhibitors. Synthesisand SAR studies. Bioorg. Med. Chem. Lett., 2002, 12, 3551-3555.
184. Huong, D.T.L.; Dat, N.T.; Minh, C.V.; Kang, J.S.; Kim, Y.H. Monoamine oxidase inhibitors from Aquilaria agallocha. Nat.Prod. Sci., 2002, 8, 30-33.
185. Seon, H.J.; Xiang, H.H.; Seong, S.H.; Hwang, J.S.; Hwang, J.H.; Dongho, L.; Myung, K.L.; Jai, S.R.; Bang, Y.H. Monoamine oxidaseinhibitory coumarins from the aerial parts of Dictamnus albus.Arch. Pharm. Res., 2006, 29, 1119-1124.
186. Passos, C.S.; Simoes-Pires, C.A.; Nurisso, A.; Soldi, T.C.; Kato, L.; de Oliveira, C.M.; de Faria, E.O.; Marcourt, L.; Gottfried, C.; Carrupt, P.A.; Henriques, A.T. Indole alkaloids of Psychotria asmultifunctional cholinesterases and monoamine oxidases inhibitors.Phytochemistry, 2013, 86, 8-20.
187. Van der Walt, E.M.; Milczek, E.M.; Malan, S.F.; Edmondson, D.E.; Castagnoli N, Jr.; Bergh, J.J.; Petzer, J.P. Inhibition of monoamineoxidase by (E)-styrylisatin analogues. Bioorg. Med. Chem.Lett., 2009, 19, 2509-2513.
188. Pretorius, J.; Malan, S.F.; Castagnoli N Jr.; Bergh, J.J.; Petzer, J.P. Dual inhibition of monoamine oxidase B and antagonism of theadenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg. Med. Chem., 2008, 16, 8676-8684.
189. Pan, X.; Kong, L.D.; Zhang, Y.; Cheng, C.H.K.; Ren-Xiang, T. Invitro inhibition of rat monoamine oxidase by liquiritigenin andisoliquiritigenin isolated from Sinofranchetia chinensis. ActaPharmacol. Sin., 2000, 21, 949-953.
190. Saaby, L.; Rasmussen, H.B.; Jager, A.K. MAO-A inhibitory activityof quercetin from Calluna vulgaris (L.) Hull. J. Ethanopharmacol.,2009, 121, 178-181.
191. Zhou, C.X.; Kong, L.D.; Ye, W.C.; Cheng, C.H.K.; Tan, R.X.Inhibition of xanthine and monoamine oxidases by stilbenoids fromVeratrum taliense. Planta Med., 2001, 67, 158-161.
192. Ren, L.X.; Luo, Y.F.; Li, X.; Zuo, D.Y.; Wu, Y.L. Antidepressantlike effects of Sarsasapogenin from Anemarrhena asphodeloidesBUNGE (Liliaceae). Biol. Pharm. Bull., 2006, 29, 2304-2306.
193. Kulkarni, S.K.; Bhutani, M.K.; Bishnoi, M. Antidepressant activityof curcumin: involvement of serotonin and dopamine system. Psychopharm,2008, 201, 435-442.
194. Dar, A.; Khatoon, S. Antidepressant activities of Areca catechufruit extract. Phytomedicine, 1997, 4, 41-45.
195. Dar, A.; Khatoon, S. Behavioral and biochemical studies of dichloromethanefraction from Areca catechu. Nut. Pharm. Biochem.Behavior., 2000, 65(1), 1-6.
196. Kong, L.D.; Christopher, H.K.; Tan, R.X. Inhibition of MAO Aand B by some plant-derived alkaloids, phenols and anthraquinones.J. Ethnopharmacol., 2004, 91, 351-355.
197. Meena, J.; Ojha, R.; Muruganandam, A.V.; Krishnamurthy, S. Asparagus racemosus competitively inhibits in vitro the acetylcholineand monoamine metabolizing enzymes. Neurosci. Lett., 2011,503, 6-9.
198. Ali, B.H.; Bashir, A.K.; Tanira, M.O.M.; Medvedev, A.E.; Jarrett, N.; Sandler, M.; Glover, V. Effect of extract of Rhazya stricta, atraditional medicinal plant, on rat brain tribulin. Pharmacol. Biochem.Behav., 1998, 59, 671-675.
199. Benvenga, M.J.; Leander, J.D. Antidepressant-like effect ofLY228729 as measured in the rodent swim paradigm. Eur. J.Pharmacol., 1993, 239, 249-252.
200. López, V.; Martín, S.; Gómez-Serranillos, M.P.; Carretero, M.E.; Jäger, A.K.; Calvo, M.I. Neuroprotective and neurological propertiesof Melissa officinalis. Neurochem. Res., 2009, 34, 1955-1961.
201. Mechan, A.O.; Fowler, A.; Seifert, N.; Rieger, H.; Wöhrle, T.; Etheve, S.; Wyss, A.; Schüler, G.; Colletto, B.; Kilpert, C.; Aston, J.; Elliott, J.M.; Goralczyk, R.; Mohajeri, M.H. Monoamine reuptakeinhibition and mood-enhancing potential of a specified oreganoextract. Br. J. Nutr., 2011, 105, 1150-1163.
202. Pardon, M.C.; Joubert, C.; Perez-Díaz, F.; Christen, Y.; Launay, J.M.; Cohen-Salmon, C. In vivo regulation of cerebral monoamineoxidase activity in senescent controls and chronically stressed miceby long-term treatment with Ginkgo biloba extract (EGb 761).Mech. Ageing Dev., 2000, 113, 157-168.
203. Imanshahidi, M.; Hosseinzadeh, H. The pharmacological effects ofSalvia species on the central nervous system. Phytother. Res., 2006,20, 427-437.
204. Haraguchi, H.; Tanaka, Y.; Kabbash, A.; Fujioka, T.; Ishizu, T.; Yagi, A. Monoamine oxidase inhibitors from Gentiana lutea. Phytochemistry,2004, 65, 2255-2260.
205. Han, Y.N.; Noh, D.B.; Han, D.S. Studies on the monoamine oxidaseinhibitors of medicinal plants I. Isolation of MAO-B inhibitorsfrom Chrysanthemum indicum. Arch. Pharm. Res., 1987, 10, 142-147.
206. Rocha, L.; Marston, A.; Kaplan, A.C.; Evans, H.S.; Thull, U.; An antifungal γ-pyrone and xanthones with monoamine oxidaseinhibitory activity from Hypericum brasiliense. Phytochemistry,1994, 36, 1381-1385.
207. Gnerre, C.; Thull, U.; Gaillard, P.; Carrupt, P.A.; Testa, B.; Fernandes, E.; Silva, F.; Pinto, M.; Pinto, M.M.M.; Wolfender, J.L.; Hostettmann, K.; Cruciani, G. Natural and synthetic xanthones asmonoamine oxidase inhibitors, biological assay and 3D-QSAR.Helv. Chim. Acta., 2001, 84, 552-570.
208. Wu, W.R.; Zhu, X.Z. Involvement of monoamine oxidase inhibitionin neuroprotective and neurorestorative effects of Ginkgobiloba extract against MPTP-induced nigrostriatal dopaminergictoxicity in C57 mice. Life Sci., 1999, 65, 157-164.
209. Sloley, B.D; Urichuk, L.J.; Morley, P.; Durkin, J.; Shan, J.J.; Pang, P.K.; Coutts, R.T. Identification of kaempferol as a monoamineoxidase inhibitor and potential Neuroprotectant in extracts ofGinkgo biloba leaves. J. Pharm. Pharmacol., 2000, 52, 451-459.
210. Kong, L.D.; Tan, R.X.; Woo, A.Y.; Cheng, C.H. Inhibition of ratbrain monoamine oxidase activities by psoralen and isopsoralen:implications for the treatment of affective disorders. Pharmacol.Toxicol., 2001, 88, 75-80.
211. Kong, L.D.; Cheng, C.H.; Tan, R.X. Monoamine oxidase inhibitorsfrom rhizoma of Coptis chinensis. Planta. Med., 2001, 67, 74-76.
212. Jo, Y.S.; Houng, D.T.L.; Bae, K.; Lee, M.K.; Kim, Y.H.; Monoamineoxidase inhibitory coumarin from Zanthoxylum schinifolium.Planta. Medica., 2002, 68, 84-85.
213. Lin, R.D.; Hou, W.C.; Yen, K.Y.; Lee, M.H.; Inhibition of monoamineoxidase B (MAO-B) by Chinese herbal medicines. Phytomedicine,2003, 10, 650-656.
214. Hou, W.C.; Lin, R.D.; Chen, C.T.; Lee, M.H. Monoamine oxidaseB (MAO-B) inhibition by active principles from Uncaria rhynchophylla.J. Ethnopharmacol., 2005, 100, 216-220.
215. Tao, G.; Irie, Y.; Li, D.J.; Keung, W.M. Eugenol and its structuralanalogs inhibit monoamine oxidase A and exhibit antidepressantlikeactivity. Bioorg. Med. Chem., 2005, 13, 4777-4788.
216. Hwang, J.S.; Lee, S.A.; Hong, S.S.; Lee, K.S.; Lee, M.K.; Hwang, B.Y.; Ro, J.S. Monoamine oxidase inhibitory components from theroots of Sophora flavescens. Arch. Pharm. Res., 2005, 28, 190-194.
217. Han, X.H.; Hong, S.S.; Hwang, J.S.; Jeong, S.H.; Hwang, J.H.; Lee, M.H.; Lee, M.K.; Lee, D.; Ro, J.S.; Hwang, B.Y. Monoamineoxidase inhibitory constituents from the fruits of Cudrania tricuspidata. Arch. Pharm. Res., 2005, 28, 1324-1327.
218. Jeong, S.H.; Han, X.H; Hong, S.S.; Hwang, J.S.; Hwang, J.H.; Lee, D; Lee, M.K.; Ro, J.S.; Hwang, B.Y. Monoamine oxidase inhibitorycoumarins from the aerial parts of Dictamnus albus. Arch.Pharm. Res., 2006, 29, 1119-1124.
219. Chimenti, F.; Cottiglia, F.; Bonsignore, L.; Casu, L.; Casu, M.; Floris, C.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.; Trombetta, G.; Loizzo, A.; Guarino, I. Quercetin as the active principle of hypericum hircinumexerts a selective inhibitory activity against MAO-A: Extraction,biological analysis, and computational study. J. Nat.Prod., 2006, 69, 945-949.
220. Han, X.H.; Hong, S.S.; Hwang, J.S.; Lee, M.K.; Hwang, B.Y.; Ro, J.S. Monoamine oxidase inhibitory components from Cayratia japonica. Arch. Pharm. Res., 2007, 30, 13-17.
221. Lee, S.A.; Hong, S.S.; Han, X.H.; Hwang, J.S.; Oh, G.J.; Lee, K.S.; Lee, M.K.; Hwang, B.Y.; Ro, J.S. Piperine from the fruits of Piperlongum with inhibitory effect on monoamine oxidase and antidepressant-like activity. Chem. Pharm. Bull. (Tokyo)., 2005, 53, 832-835.
222. Lee, S.A.; Hwang, J.S.; Han, X.H.; Lee, C.; Lee, M.H.; Choe, S.G.; Hong, S.S.; Lee, D.; Lee, M.K.; Hwang, B.Y. Methylpiperate de rivatives from Piper longum and their inhibition of monoamineoxidase. Arch. Pharm. Res., 2008, 31, 679-683.
223. Li, S.; Wang, C.; Li, W.; Koike, K.; Nikaido, T.; Wang, M.W. Antidepressant-like effects of piperine and its derivative, antiepilepsirine.J. Asian. Nat. Prod. Res., 2007, 9, 421-430.
224. Van Diermen D.; Marston, A.; Bravo, J.; Reist, M.; Carrupt, P.A.; Hostettmann, K. Monoamine oxidase inhibition by Rhodiola roseaL. roots, J. Ethnopharmacol., 2009, 122, 397-401.
225. Aiyegoro, O.A.; Van Dyk, S. The antioxidant properties, cytotoxicityand monoamine oxidase inhibition abilities of the crude dichloromethaneextract of Tarchonanthus camphoratus L. leaves.Afr. J. Biotechnol., 2011, 10, 17297-17304.
226. Al-Baghdadi, O.B.; Prater, N.I.; Van der Schyf, C.J.; Geldenhuys, W.J. Inhibition of monoamine oxidase by derivatives of piperine,an alkaloid from the pepper plant Piper nigrum, for possible use inParkinson's disease. Bioorg. Med. Chem. Lett., 2012, 22, 7183-7188.
227. Moloudizargari, M.; Mikaili, P.; Aghajanshakeri, S.; Asghari, M.H.; Shayegh, J. Pharmacological and therapeutic effects ofPeganum harmala and its main alkaloids. Pharmacogn. Rev., 2013,7, 199-212.
228. Samoylenko, V.; Rahman, Md. M.; Tekwani, B.L.; Trpathi, L.M.; Wang, Y.H.; Khan, S.I.; Khan, I.A.; Miller, L.S.; Joshi, V.C.; Muhammad, I. Banisteriopsis caapi, a unique combination of MAOinhibitory and antioxidative constituents for the activities relevantto neurodegenerative disorders and Parkinson’s disease. J. Ethnopharmacol.,2010, 127, 357-367.
229. Van Diermen D.; Marston, A.; Bravo, J.; Reist, M.; Carrupt, P.A.; Hostettmann, K. Monoamine oxidase inhibition by Rhodiola roseaL. roots, J. Ethnopharmacol., 2009, 122, 397-401.
230. Han, X.H.; Hong, S.S.; Hwang, J.S.; Lee, M.K.; Hwang, B.Y.; Ro, J.S. Monoamine oxidase inhibitory components from Carytia japonica. Arch. Pharm. Res., 2007, 30, 13-17.
231. Lee, M.H.; Lin, R.D.; Shen, L.Y.; Yang, L.L.; Yen, K.Y.; Hou, W.C. Monoamine oxidase B and free radical scavenging activitiesof natural flavonoids in Melastoma candidum D. Don. J. Agr. FoodChem., 2001, 49, 5551-5555.
232. Olsen, H.T.; Stafford, G.I.; van Staden, J.; Chistensen, S.B.; Jäger, A.K. Isolation of MAO-inhibitor naringenin from Mentha aquaticL. J. Ethnopharmacol., 2008, 117, 500-502.
233. Deng, S.; West, B.J. Antidepressant effects of Noni fruit and itsactive principals. Asian J. Med. Sci., 2011, 3, 79-83.
234. Dreiseitel, A.; Korte, G.; Schereir, P.; Oehme, A.; Locher, S.; Domani, M.; Hajak, G.; Sand, P.G. Berry anthocyanins and their aglyconsinhibit monoamine oxidases A and B. Pharmacol. Res., 2009,59, 306-311.
235. Bruhlmann, C.; Marston, A.; Hostettmann, K.; Carrupt, P.A.; Testa, B. Screening of non-alkaloidal natural compounds as acetyl cholinesteraseinhibitors. Chem. Biodivers., 2004, 1, 819-829.
236. Dimitrov, M.; Nikolova, I.; Benbasat, N.; Kitanov, G.; Danchev, N. Acute toxicity, antidepressive and MAO inhibitory activity ofmangiferin isolated from Hypericum aucheri. Biotechnol. & Biotechnol.Eq., 2011, 25, 2668-2671.
237. Uebelhack, R.; Franke, L.; Schewe, H.J. Inhibition of plateletMAO-B by Kava pyrone-enriched extract from Piper MethisticumForster (Kava Kava). Pharmacopsychiat., 1998, 31, 187-192.
238. Han, Y.N.; Choo, Y.; Lee, Y.C.; Moon, Y.I.; Kim, S.D.; Choi, J.W. Monoamine oxidase B inhibitors from the fruits of Opuntia ficusindicavar. saboten. Arch. Pharm. Res., 2001, 24, 51-54.
239. Dittmann, K.; Gerhäuser, C.; Klimo, K.; Hamburger, M. HPLCBased activity profiling of Salvia miltiorrhiza for MAO A andiNOS inhibitory activities. Planta Med., 2004, 70, 909-913.
240. Lee, S.J.; Chung, H.Y.; Lee, I.K.; Oh, S.U.; Yoo, I.D. Phenolicswith inhibitory activity on mouse brain monoamine oxidase (MAO)from whole parts of Artemisia vulgaris L (Mugwort). Food Sci.Biotechnol., 2000, 9, 179-182.
241. Lee, S.S.; Kai, M.; Lee, M.K. Inhibitory effects of Sanguinarine onmonoamine oxidase activity in mouse brain. Phytother. Res., 2001,15, 167-169.
242. Hwang, J.H.; Hong, S.S.; Han, X.H.; Hwang, J.S.; Lee, D.; Lee, H. Prenylated xanthones from the root bark of Cudrania tricuspidata.J. Nat. Prod., 2007, 70, 1207-1209.
243. Gacche, R.N.; Shaikh, R.U.; Chapole, S.M.; Jadhav, A.D.; Jadhav, S.G. Kinetics of inhibition of monoamine oxidase using cymbopogonmartinii (Roxb.) Wats.: A potential antidepressant herbalingredient with antioxidant activity. Ind. J. Clin. Biochem., 2011,26, 303-308
244. Thomas, S.J.; Shin, M.; McInnis, M.G.; Bostwick, J.R. Combinationtherapy with monoamine oxidase inhibitors and other antidepressantsor stimulants: strategies for the management of treatmentresistantdepression. Pharmacotherapy, 2015, 35, 433-449.
245. Engelbrecht, I.; Petzer, J.P.; Petzer, A. The synthesis and evaluationof sesamol and benzodioxane derivatives as inhibitors ofmonoamine oxidase. Bioorg. Med. Chem. Lett., 2015, 25, 1896-1900.
246. Mostert, S.; Petzer, A.; Petzer, J.P. Indanones as high-potencyreversible inhibitors of monoamine oxidase. Chem. Med. Chem.,2015, 10, 862-873.
247. Sharma S.; Moon, C.S.; Khogali, A.; Haidous, A.; Chabenne, A.; Ojo, C.; Jelebinkov, M.; Kurdi, Y.; Ebadi, M. Biomarkers of parkinson’sdisease (recent update). Neurochem. Int., 2013, 63, 201-229.
248. Sharma S.; Ebadi, M. In: Antioxidant Targeting in NeurodegenerativeDisorders; I. Laher, Ed.; Springer Verlag: Germany, 2013;Chapter 85, pp. 1-30.
249. Sharma S.; Ebadi, M. Charnoly body as a Universal Biomarker ofCell Injury. Biomark. Gen. Med., 2014, 6, 89-98.
250. Sharma S.K., Ebadi, M. Metallothionein attenuates 3-morpoholinosydnonimone (SIN-1)-induced oxidative and nitrativestress in dopaminergic neurons. Antioxid. Redox. Signal., 2003, 5,251-264.
251. Ebadi, M., Sharma S. Peroxynitrite and mitochondrial dysfunctionin the pathogenesis of Parkinson’s disease. Antioxid. Redox. Signal.,2003, 5, 319-335.
252. Sharma S.; Carlson, E.; Ebadi, M. The neuroprotective actions ofselegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in dopaminergic neurons. J. Neurocytol., 2003,32, 329-343.
253. Sharma S and Ebadi, M. Significance of Metallothioneins in AgingBrain. Neurochem. Int., 2014, 65, 40-48.
254. Sharma S. Beyond Diet and Depression, 2nd Vol.; Book NovaScience Publishers: New York, 2015.
255. Ly, V.T.; Brock, B. Effects of CYP inhibitors on precocene I metabolismand toxicity in rat liver slices. Chem. Biol. Interact., 2011,193, 109-118.
256. Da Prada, M.; Zurcher, G.; Wüthrich, I.; Haefely, W.E. Ontyramine, food, beverages and the reversible MAO inhibitor moclobemide.J. Neural. Transm. Suppl., 1988, 26, 31-56.